Cargando…

Toceranib phosphate (Palladia) reverses type 1 diabetes by preserving islet function in mice

In recent years, strategies targeting β-cell protection via autoimmune regulation have been suggested as novel and potent immunotherapeutic interventions against type 1 diabetes mellitus (T1D). Here, we investigated the potential of toceranib (TOC), a receptor-type tyrosine kinase (RTK) inhibitor us...

Descripción completa

Detalles Bibliográficos
Autores principales:	KISHI, Kazuhisa, YONEZAWA, Tomohiro, KAJI, Noriyuki, GOTO, Momo, NONOSHITA, Yuma, IIO, Aki, TSURU, Yoshiharu, HORI, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Veterinary Science 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372262/ https://www.ncbi.nlm.nih.gov/pubmed/37258127 http://dx.doi.org/10.1292/jvms.23-0154

Ejemplares similares

Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs
por: YAMAZAKI, Hiroki, et al.
Publicado: (2017)

Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma
por: Musser, Margaret L., et al.
Publicado: (2021)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs
por: Berger, Erika P., et al.
Publicado: (2018)

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor
por: Halsey, Charles HC, et al.
Publicado: (2014)

Noninvasive monitoring of muscle atrophy and bone metabolic disorders using dual-energy X-ray absorptiometry in diabetic mice
por: Kishi, Kazuhisa, et al.
Publicado: (2022)

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)
por: Musser, Margaret L., et al.
Publicado: (2018)

Feline restrictive orbital myofibroblastic sarcoma treated with toceranib phosphate (Palladia) as adjuvant chemotherapy: A case study of one cat
por: Komatsu, Hiroyuki, et al.
Publicado: (2023)

Development of a quantitative method for evaluating small intestinal motility using ultrasonography in mice
por: Kishi, Kazuhisa, et al.
Publicado: (2019)

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs
por: Tjostheim, S.S., et al.
Publicado: (2016)

Hyperglycemia in the early stages of type 1 diabetes accelerates gastric emptying through increased networks of interstitial cells of Cajal
por: Kishi, Kazuhisa, et al.
Publicado: (2019)

A Close Relationship Between Networks of Interstitial Cells of Cajal and Gastrointestinal Transit In Vivo
por: Kishi, Kazuhisa, et al.
Publicado: (2020)

Effects of Toceranib Phosphate on the Hypothalamic‐Pituitary‐Thyroid Axis in Tumor‐Bearing Dogs
por: Hume, K.R., et al.
Publicado: (2017)

Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs
por: Yamazaki, Hiroki, et al.
Publicado: (2020)

Toceranib phosphate-associated nephrotic syndrome in a dog: a case report
por: Remerowski, Shannon M., et al.
Publicado: (2021)

Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus
por: KIMURA, Hitomi, et al.
Publicado: (2022)

Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma
por: OSADA, Hironari, et al.
Publicado: (2023)

Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
por: Burton, J.H., et al.
Publicado: (2015)

Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate
por: Todd, Johanna E, et al.
Publicado: (2020)

Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate
por: ICHIMATA, Masanao, et al.
Publicado: (2021)

Transcriptome analysis of mesenchymal stromal cells of the large and small intestinal smooth muscle layers reveals a unique gastrontestinal stromal signature
por: Chaen, Takashi, et al.
Publicado: (2023)

Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs
por: Olsen, Jaime A., et al.
Publicado: (2018)

A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
por: Coto, Giovanna M., et al.
Publicado: (2021)

Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009–2019)
por: Sheppard‐Olivares, Sabina, et al.
Publicado: (2022)

Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines
por: Korec, Daniela I., et al.
Publicado: (2021)

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs
por: Maeda, Shingo, et al.
Publicado: (2022)

Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer
por: Maeda, Shingo, et al.
Publicado: (2022)

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose
por: Bernabe, Luis Feo, et al.
Publicado: (2013)

Transcriptome of Two Canine Prostate Cancer Cells Treated With Toceranib Phosphate Reveals Distinct Antitumor Profiles Associated With the PDGFR Pathway
por: Kobayashi, Priscila E., et al.
Publicado: (2020)

Interstitial cells of Cajal in gastrointestinal inflammatory diseases
por: Kaji, Noriyuki, et al.
Publicado: (2023)

Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs
por: Heaton, Caitlin M., et al.
Publicado: (2020)

Liver fibrosis-induced muscle atrophy is mediated by elevated levels of circulating TNFα
por: Kurosawa, Tamaki, et al.
Publicado: (2021)

Palmar–plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report
por: Kim, Eunjoo, et al.
Publicado: (2023)

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma
por: Gardner, Heather L., et al.
Publicado: (2015)

A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma
por: Rippy, Sarah B., et al.
Publicado: (2016)

Erratum to: A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma
por: Rippy, Sarah B., et al.
Publicado: (2016)

Plasma cytokeratin‐18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib
por: Kovac, Rachel L., et al.
Publicado: (2018)

Case report: Toceranib as adjuvant chemotherapy in a dog with incompletely resected combined hepatocellular-cholangiocarcinoma
por: Kim, Sang-Won, et al.
Publicado: (2023)

Synergistic Effect of Toceranib and Nanohydroxyapatite as a Drug Delivery Platform—Physicochemical Properties and In Vitro Studies on Mastocytoma Cells
por: Sobierajska, Paulina, et al.
Publicado: (2022)

c‐Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine
por: Weishaar, K.M., et al.
Publicado: (2017)

Case report: Adjuvant therapy with toceranib for an incompletely resected renal cell carcinoma with suspected pulmonary metastasis in a dog
por: Lee, Da-Eun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0r2d8jei1ujqss92v324ctndto